AFJK vs CLOV vs GDRX vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 0. 6% for GoodRx Holdings, Inc. (GDRX). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Clover Health Investments, Corp. (CLOV) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GoodRx Holdings, Inc.

(GDRX) is the cheapest at 33. 3x versus Aimei Health Technology Co. , Ltd at 251. 0x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x.

Over the past 5 years, Aimei Health Technology Co.

, Ltd (AFJK) delivered a total return of +320. 4%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: AFJK returned +320. 4% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aimei Health Technology Co.

, Ltd (AFJK) is the lower-risk stock at 0. 23β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 929% more volatile than AFJK relative to the S&P 500. On balance sheet safety, GoodRx Holdings, Inc. (GDRX) carries a lower debt/equity ratio of 10% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 0. 6% for GoodRx Holdings, Inc. (GDRX). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 56. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 18. 1% to $3. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aimei Health Technology Co.

, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +320. 4% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AFJK: +320. 4%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AFJK (Financial Services) and CLOV (Healthcare) and GDRX (Healthcare) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AFJK is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock; GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.